Vaccines:

Indications for: PRIORIX

Active immunization for the prevention of measles, mumps, and rubella.

Clinical Trials:

The approval of Priorix was based on safety data from 6 clinical studies that assessed Priorix in a total of 12,151 participants, of which 8780 were between 12 to 15 months of age, 2917 were between 4 to 6 years of age, and 454 were 7 years of age and older.

 In the clinical studies, participants received at least 1 dose of either Priorix or a US-licensed MMR virus vaccine, live (M-M-R® II). Efficacy was demonstrated based on comparative immunogenicity data with M-M-R II.

Concomitant Administration With Havrix, Varivax, and Prevnar 13

  • Concomitant administration of Priorix or M-M-R II with Havrix and Varivax was evaluated in children 12 through 15 months of age.
  • Children enrolled in the US also received Prevnar 13.
  • Results showed no evidence that Priorix interfered with the antibody responses to these vaccines relative to the antibody responses when M-M-R II was concomitantly administered. 

Concomitant Administration With Kinrix and Varivax

  • Concomitant administration of Priorix or M-M-R II with Kinrix and Varivax was evaluated in children 4 through 6 years of age.
  • Results showed no evidence that Priorix interfered with the antibody responses to these vaccines relative to the antibody responses when M-M-R II was concomitantly administered.

Adults and Children:

<12 months: not established. Each dose is 0.5mL. Give by SC inj. First dose at 12–15 months of age, second dose at 4–6yrs of age. If Priorix is not given according to this schedule and 2 doses are recommended: separate the first and second dose by a minimum of 4 weeks. Priorix may be given as a second dose to individuals who received a first dose of another measles, mumps and rubella-containing vaccine.

PRIORIX Contraindications:

History of severe allergic reactions after a previous dose of any measles, mumps, and rubella virus-containing vaccine. Severe humoral or cellular (primary or acquired) immunodeficiency. Pregnancy (during and for 1 month after vaccination).

PRIORIX Warnings/Precautions:

Have epinephrine inj available. Risk of febrile seizures or vaccine virus transmission. Latex allergy. Vaccination may not protect all susceptible individuals. Nursing mothers.

PRIORIX Classification:

MMR.

PRIORIX Interactions:

Concomitant immune globulins, other blood products may interfere with the expected immune response to the vaccine. May cause a temporary suppression of tuberculin reactivity. Avoid false (–) results by administering tuberculin test any time before, simultaneously with, or at least 4 weeks after vaccination.

Adverse Reactions:

Local reactions (eg, pain, redness, swelling), irritability, loss of appetite, drowsiness, fever; thrombocytopenia, thrombocytopenic purpura, syncope.

Generic Drug Availability:

NO

How Supplied:

Single-dose vials—10 (w. prefilled syringes of diluent)